Grifols | GRFS - Current Assets

Stock Price
7.66
Daily Change
-0.13 -1.67%
Monthly
-10.93%
Yearly
-1.29%
Q2 Forecast
7.46

Grifols reported EUR5.96B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Arca Biopharma USD 395.25M 51.39M Mar/2026
aTyr Pharma USD 67.58M 178.23M Mar/2026
Bio Path USD 663K 17K Sep/2025
Brainstorm Cell Therapeutics USD 184K 123K Mar/2026
Capricor Therapeutics USD 283.09M 39.85M Mar/2026
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Grifols EUR 5.96B 316.31M Dec/2025
Immunic USD 188.76M 165.89M Mar/2026
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
TherapeuticsMD USD 11.82M 303K Jun/2024